CAS NO: | 1228763-95-8 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
Monalizumab 是一种首创的靶向自然杀伤细胞群 2A (NKG2A) 的免疫检查点抑制剂。Monalizumab 是一种人源化抗 NKG2A 的单克隆抗体,可增加 IFN-γ 产生,从而促进自然杀伤细胞功能。Monalizumab 可用于头颈部鳞状细胞癌 (HNSCC) 的研究。
Cas No. | 1228763-95-8 |
别名 | 莫那利珠单抗 |
溶解度 | Soluble in water |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2]. [1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263. |